Literature DB >> 15224973

Management of lung cancer in older adults.

Arti Hurria1, Mark G Kris.   

Abstract

Lung cancer is the leading cause of cancer death in the United States. At the time of diagnosis, most patients are older than 65 years and have Stage III or IV disease. More than 80% of patients have non-small cell lung cancer and the rest have small cell lung cancer. Age is not a significant prognostic factor for overall survival and response to treatment for patients with either type of lung cancer. Treatment options should be tailored to older patients based on the same selection process and benefits seen in the population as a whole. This article reviews the available data regarding surgery, radiation, and systemic treatment for older patients with lung cancer and considers the role of geriatric assessment in the evaluation of older patients.

Entities:  

Mesh:

Year:  2003        PMID: 15224973     DOI: 10.3322/canjclin.53.6.325

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  19 in total

1.  Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.

Authors:  Arthur Cho; Jin Hur; Yoo Jin Hong; Hye-Jeong Lee; Young Jin Kim; Sae Rom Hong; Young Joo Suh; Dong Jin Im; Yun Jung Kim; Jae Seok Lee; Hyo Sup Shim; Byoung Wook Choi
Journal:  Tumour Biol       Date:  2015-10-02

2.  Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer.

Authors:  F Chen; P Hu; N Liang; J Xie; S Yu; T Tian; Jingxin Zhang; G Deng; Jiandong Zhang
Journal:  Clin Transl Oncol       Date:  2017-07-24       Impact factor: 3.405

3.  Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience.

Authors:  Regina Gironés Sarrió; María Dolores Torregrosa; Pedro López; José Gómez-Codina; Rafael Rosell
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

4.  Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.

Authors:  Dong Xue; Shuyan Han; Shantong Jiang; Hong Sun; Yanzhi Chen; Yuanqing Li; Wei Wang; Ye Feng; Ke Wang; Pingping Li
Journal:  Med Oncol       Date:  2015-03-15       Impact factor: 3.064

5.  Small cell lung cancer.

Authors:  Gregory P Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura Qm Chow; Robert J Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W Loo; Robert E Merritt; Cesar A Moran; Harvey B Niell; Janis O'Malley; Jyoti D Patel; Neal Ready; Charles M Rudin; Charles C Williams; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-01-01       Impact factor: 11.908

6.  Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.

Authors:  Ali Osman Kaya; Suleyman Buyukberber; Mustafa Benekli; Ugur Coskun; Alper Sevinc; Muge Akmansu; Ramazan Yildiz; Banu Ozturk; Emel Yaman; Mehmet Emin Kalender; Okan Orhan; Deniz Yamac; Aytug Uner
Journal:  Med Oncol       Date:  2009-02-26       Impact factor: 3.064

7.  A comparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: a population-based investigation.

Authors:  Hyun-Ju Seo; Seok-Jun Yoon; Sang-Il Lee; Kun Sei Lee; Young Ho Yun; Eun-Jung Kim; In-Hwan Oh
Journal:  BMC Health Serv Res       Date:  2010-08-13       Impact factor: 2.655

8.  Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice.

Authors:  Zixing Wang; Wei Han; Weiwei Zhang; Fang Xue; Yuyan Wang; Yaoda Hu; Lei Wang; Chunwu Zhou; Yao Huang; Shijun Zhao; Wei Song; Xin Sui; Ruihong Shi; Jingmei Jiang
Journal:  Chin J Cancer       Date:  2017-07-14

9.  Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.

Authors:  Jennifer Garst
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

10.  Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.

Authors:  Hisao Imai; Keita Mori; Nodoka Watase; Toshifumi Kazama; Sakae Fujimoto; Kyoichi Kaira; Masanobu Yamada; Koichi Minato
Journal:  Thorac Cancer       Date:  2016-08-01       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.